Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

R&D Expenses: Research and development expenses were $141.3 million for 2024, as compared to $97.1 million for 2023. This increase was driven by the progression of our existing clinical trials, ...

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks ...

HYDERABAD: India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of ...

Presentation Date / Time: Saturday, March 8, 2025; 1 p.m. PST ...

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ...

The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available on ...